News >

Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL

Angelica Welch
Published: Tuesday, Nov 14, 2017

Loretta J. Nastoupil, MD

Loretta J. Nastoupil, MD
The first known triplet regimen of a CD20 monoclonal antibody plus a PI3K-delta inhibitor and a BTK inhibitor demonstrated clinical activity and tolerability in patients with advanced chronic lymphocytic leukemia (CLL), among other subsets of non-Hodgkin lymphoma (NHL), according to phase I findings.

at ASCO, lead investigator Loretta J. Nastoupil, MD, an associate professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the findings of this phase I trial.

OncLive: Can you provide an overview of this study?

Nastoupil: We presented a phase I study with a novel 3-drug combination of ublituximab, which is a glycoengineered chimeric CD20 antibody that binds to a unique epitope, in combination with TGR-1202, or umbralisib, and the BTK inhibitor ibrutinib. Ublituximab is a novel CD20 antibody that is currently under investigation primarily in CLL and in phase II studies in indolent NHL. TGR-1202, or umbralisib, is a novel PI3K inhibitor that we think has more selectivity for the PI3K-delta isoform of the PI3K enzymes.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x